Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Vasomune Therapeutics

Vasomune Therapeutics
Out of Business LATEST DEAL TYPE

Developer of biotechnology platform intended to help with the treatment of target diseases associated with vascular dysfunction and destabilization. The company's drug candidate targets a signaling molecule in the vasculature responsible for regulating barrier defense and the host vascular response to injury enabling doctors to help patients to fight against illness by modifying a cellular response to disease.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 661 University Avenue
  • Toronto, Ontario M5G 1M1
  • Canada

+1 (416) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Vasomune Therapeutics’s full profile, request a free trial.

Vasomune Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 01-Feb-2019 00.00 Completed Out of Business
2. Seed Round 20-Oct-2014 00.00 00.00 Completed Product Development
1. Grant 01-Apr-2014 $27K Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Vasomune Therapeutics Executive Team (6)

Name Title Board
Douglas Hamilton President & Chief Executive Officer
Paul Van Slyke Ph.D Co-Founder & Chief Scientific Officer
Steven Chackowicz Executive
Michael Midmer Chief Operating Officer
Parimal Nathwani Chairman

1 Former Executive

You’re viewing 5 of 6 executives. Get the full list »

Vasomune Therapeutics Board Members (5)

Name Representing Role Since Contact
Michael Young Vasomune Therapeutics Board Member 000 0000
Niclas Stiernholm Ph.D Self Board Member 000 0000
Parimal Nathwani Self Chairman 000 0000
Raphael Hofstein Ph.D Toronto Innovation Acceleration Partners Board Member 000 0000

1 Former Board Member

You’re viewing 4 of 5 board members. Get the full list »